EcoDrugPlus

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSSPAG00000023154
Gene Symbol: ACHE
3 Cross references
231 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSSPAG00000008453
Gene Symbol: ACVR2B
3 Cross references
193 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSSPAG00000006024
Gene Symbol: ACVR2B
3 Cross references
195 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSSPAG00000020148
Gene Symbol: ADORA1
4 Cross references
204 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSSPAG00000006062
Gene Symbol: ADORA2A
3 Cross references
198 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSSPAG00000013828
Gene Symbol: ADORA2B
1 Cross references
198 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSSPAG00000002502
Gene Symbol: ADORA2B
3 Cross references
198 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSSPAG00000001996
Gene Symbol: ADORA3
3 Cross references
144 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSSPAG00000023506
Gene Symbol: ADORA3
3 Cross references
39 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSSPAG00000002714
Gene Symbol: ADA
3 Cross references
216 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSSPAG00000006385
Gene Symbol: LOC103368126
3 Cross references
173 Possible Orthologues:

Adenosine Receptor A2a-Like

Ensembl ID : ENSSPAG00000007665
Gene Symbol: LOC103358983
3 Cross references
189 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).